Загрузка...
Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients
The DR-70® (FDP) test was the first cancer test cleared by USFDA for monitoring colorectal cancer (CRC) since Carcinoembryonic Antigen (CEA) in 1982. Conservatively, 50% of biopsy-positive CRC patients have negative CEA values. DR-70 and CEA values were compared for 113 CRC monitoring patients. Tota...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Taylor & Francis
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2872273/ https://ncbi.nlm.nih.gov/pubmed/20391025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15321811003617438 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|